Article
October 13, 2025
Expert Insights: Dawn Manley on Injectable Drug Delivery Solutions
Hear from Dawn Manley, Director of Global Technical Sales at PCI Pharma Services, as she shares her perspective on early engagement, innovation, and sustainability in the injectable space.
With a career that bridges both the commercial and technical sides of the pharmaceutical industry, I’ve always been driven by one goal of delivering high-quality solutions that improve patient outcomes. My journey began in pharmaceutical sales, where I worked directly with physicians and hospitals to support patient care. Over time, I transitioned into manufacturing, finding my niche in sterile injectables and combination products from pre-filled syringes and medical-grade components to advanced delivery devices.
At PCI, I’ve had the privilege of working across our Drug Development & Manufacturing division and now lead Global Technical Sales, partnering with clients and our business development teams to ensure every project runs seamlessly from concept to commercialization. Whether it’s manufacturing, device assembly in standard or custom formats, or the packaging and labelling that bring a product to market, my focus is on delivering solutions that are efficient, compliant, and tailored to each client’s unique needs.
Today, early engagement in packaging and device strategy has never been more critical. Addressing these needs upfront accelerates development timelines, manages risk, and ensures regulatory readiness, yet many still underestimate factors like lead times, user experience, and human factors, which directly influence product safety and usability.
Emerging biotechs and large pharmaceutical companies often have distinct needs when it comes to injectable packaging and delivery systems. These differences can stem from their focus on addressing unmet needs, varying levels of risk tolerance, differing economic constraints, organizational agility, and the depth of in-house expertise.
The injectable combination products market continues to evolve rapidly, driven by the rise of complex biologics, self-administration trends, and the growing emphasis on patient centricity. At PCI, we have made substantial multi-continent investments that place us at the forefront of the global advanced drug delivery solutions and drug device combination product assembly landscape. These investments include equipment, locations, and special cold storage to support both high volume programs, but also the low volume, high value growing needs.
PCI has years of experience specializing in the manufacturing of pre-filled syringes and cartridges, assembly of devices or pens, packaging and labelling, packaging design, and serialization.
Sustainability and ESG goals significantly influence packaging decisions for injectable products today by shaping the direction of packaging companies and driving consumer behavior.
PCI has embedded ESG into our daily standards and continuously measures global and site-level ESG performance against nine impact categories, winning the Bronze Sustainability Award for three consecutive years from Ecovadis.
By embedding collaboration, data-driven insights, and ESG principles into everything we do, we’re not only supporting client success but also contributing to a more sustainable and patient-focused future for injectable delivery systems.
We are committed to supporting clients at every stage of the manufacturing cycle, delivering best-in-class services efficiently and effectively.
Find out more about our fully integrated Packaging Services.
